RoboStim: Robot and tDCS Based Proprioceptive Rehabilitation After Stroke

Sponsor
University of Calgary (Other)
Overall Status
Unknown status
CT.gov ID
NCT03888326
Collaborator
(none)
30
1
3
29.9
1

Study Details

Study Description

Brief Summary

Proprioceptive deficits are common following stroke, yet current evidence-based approaches for rehabilitating proprioception are limited. Robotic rehabilitation and transcranial direct current stimulation (tDCS) are two promising technologies/techniques that can potentially be used to treat these deficits. This study's purpose is to determine whether robotic rehabilitation, specifically targeted at proprioception, has the capacity to improve proprioception in a chronic stroke population. Furthermore, it is interested in whether tDCS is able to enhance any potential improvements in proprioception as a result of robotic rehabilitation.

It is hypothesized that a robotic rehabilitation will enhance proprioception in a chronic stroke population beyond standard of care rehabilitation. It is also hypothesized that individuals receiving a combination of robotic rehabilitation and tDCS will show greater proprioceptive improvements than those just receiving robotic rehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Device: 1x1 anodal tDCS
  • Device: Sham tDCS
  • Behavioral: Robotic Rehabilitation
Phase 2

Detailed Description

Background and Rationale: Proprioception is the awareness of where our limbs are in space, in the absence of vision. It is an important sense that allows us to have control over our movement and perform many activities of daily living. Every year, approximately 62,000 Canadians suffer from a stroke. Around 50% of individuals who suffer from a stroke are left with deficits in proprioception, yet clinically very little is done to rehabilitate this sense. Two novel interventions for rehabilitating proprioception are robotic rehabilitation and Transcranial Direct Current Stimulation (tDCS). Robotic rehabilitation is potentially beneficial over conventional therapies as the number of repetitions performed in a single session can be drastically increased and these movements can be performed in a well-controlled manner, something that is more difficult in conventional therapy. It is also easy to occlude vision when performing rehabilitation in a robotic environment, meaning proprioceptive retraining can be explicitly targeted. tDCS is another technology which has the potential to enhance rehabilitation. The technique involves placing two sponge electrodes over the scalp and passing a small electrical current (1-2mA) between the two electrodes, altering the membrane potential of the brain tissue through which the current passes. When tDCS has been paired with training, it has been shown to enhance learning in both healthy and stroke populations. tDCS has yet to be investigated to improve proprioception in a stroke population.

Research Question: Can a combination of robotic rehabilitation and tDCS enhance proprioception in a chronic stroke population?

Ethics: This study has been approved by the Research Ethics Board at the University of Calgary

Design: This is a Single-Blinded, Pilot, Randomized Controlled Trial with a Sham Arm

----------Methods----------

Recruitment: 30 individuals with proprioceptive deficits beyond 6-months post-stroke are being recruited from the outpatient stroke community in Calgary, Alberta, Canada.

Randomization: Individuals are randomized into one of three groups: robotic rehabilitation plus anodal tDCS, robotic rehabilitation plus sham tDCS or standard of care rehabilitation.

Robotic Intervention: The robotic rehabilitation intervention consists of 10-days of robotic therapy in the Kinesiological Instrument for Normal and Altered Reaching Movements (KINARM) Exoskeleton. Robotic rehabilitation is conducted for 1 hour each day, on 10 consecutive days (excluding weekends). Therapy is tailored specifically towards rehabilitating proprioception and consists of a battery of 5 simple video game-like tasks. Each task is performed for 10-15 minutes each day. The order in which these tasks are completed are pseudo-randomized each day. Each day a motivation questionnaire will be completed.

tDCS Intervention: In addition to robotic rehabilitation, those in the tDCS group will also receive 20 minutes of 2mA anodal tDCS. This is applied during the first 20 minutes of each robotic session and is targeted over the ipsilesional sensory cortex. For the sham condition, the same setup will be used. Each day a tDCS tolerability questionnaire will be completed.

Assessments: All subjects will undergo 3 robotic assessments of proprioceptive performance, one at baseline (day 1), one immediately after the intervention (day 12) and one more at 3 months follow up. Two components of proprioception will be assessed during these robotic assessments (position sense and movement sense). Robotic assessments will be conducted in the same robotic exoskeleton that the therapy is delivered in.

A variety of clinical scales (Fugl-Meyer Assessment, Functional Independence Measure, and Nottingham Sensory Scale) will be collected at each time point. These will be secondary outcome measures. Performance on a robotic assessment of visually-guided reaching will also be a secondary outcome measure. All clinical assessments will be performed by a blinded assessor therapist.

Data analysis: Primary outcome measures will be analysed using a repeated measures ANOVA. Comparisons will be made between groups at each assessment time points. Secondary outcome measures and questionnaire data will also be analysed with a repeated measures ANOVA.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants are assigned to one of 3 groups for the duration of the study (robotic rehabilitation plus anodal tDCS, robotic rehabilitation plus sham tDCS, standard of care rehabilitation)Participants are assigned to one of 3 groups for the duration of the study (robotic rehabilitation plus anodal tDCS, robotic rehabilitation plus sham tDCS, standard of care rehabilitation)
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Participants are aware of whether they are in one of the robotic treatment groups but are blinded to the type of tDCS they receive (true or sham). Assessor therapist is blinded to all group allocation.
Primary Purpose:
Treatment
Official Title:
The Combined Effect of Robotic Rehabilitation and Transcranial Direct Current Stimulation on Proprioception in Chronic Stroke: a Pilot Study
Actual Study Start Date :
Mar 6, 2018
Anticipated Primary Completion Date :
Aug 31, 2020
Anticipated Study Completion Date :
Aug 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Robotic Rehabilitation plus 1x1 anodal tDCS

Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.

Device: 1x1 anodal tDCS
20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
Other Names:
  • Direct current stimulator (Soterix Medical)
  • Behavioral: Robotic Rehabilitation
    10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
    Other Names:
  • KINARM Exoskeleton (BKIN Technologies)
  • Sham Comparator: Robotic Rehabilitation plus sham tDCS

    Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.

    Device: Sham tDCS
    Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
    Other Names:
  • Direct current stimulator (Soterix Medical)
  • Behavioral: Robotic Rehabilitation
    10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
    Other Names:
  • KINARM Exoskeleton (BKIN Technologies)
  • No Intervention: Standard of Care Rehabilitation

    No additional therapy/treatment provided. The individual continues with their normal daily routine

    Outcome Measures

    Primary Outcome Measures

    1. Robotic limb position matching standardized score [Baseline, Within 1 week of completing the 10 day intervention and 3-month follow-up]

      Change in a standardized score from a baseline robotic assessment of limb position matching

    2. Robotic kinaesthesia standardized score [Baseline, Within 1 week of completing the 10 day intervention and 3-month follow-up]

      Change in a standardized score from a baseline robotic assessment of kinaesthesia (movement sense)

    Secondary Outcome Measures

    1. Change in Upper-Extremity Fugl-Meyer Assessment scores [Baseline, Within 1 week of completing the 10 day intervention and 3-month follow-up]

      Difference in subscale scores on the Upper-Extremity Fugl-Meyer Assessment - both Motor (max 66) and Sensory (max 12) components. Higher scores indicate better outcome.

    2. Change in Nottingham Sensory Assessment scores [Baseline, Within 1 week of completing the 10 day intervention and 3-month follow-up]

      Difference in subscale scores on the Nottingham Sensory Assessment - upper extremity only (Light touch, temperature, pinprick, pressure, tactile localization, bilateral simultaneous touch, proprioception - max score 12 for each subscale)

    3. Change in Functional Independence Measure score [Baseline, Within 1 week of completing the 10 day intervention and 3-month follow-up]

      Difference in score on the Functional Independence Measure (Higher scores indicate better outcome, max score 126)

    Other Outcome Measures

    1. tDCS Tolerability [During 10 day intervention period]

      The questionnaire will be completed after every session

    2. Attention/Motivation Questionnaire [During the 10 day intervention period]

      The questionnaire will be completed before and after every session. Higher scores indicate greater motivation, max score = 90

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Sex - Both male and female

    2. Age: 18 years and older

    3. Stroke onset: >6 months prior to enrolment

    4. Stroke type: Hemorrhagic and ischaemic

    5. Evidence of proprioceptive deficits as determined by a robotic assessment

    6. Ability to follow simple 3-step commands

    Exclusion Criteria:
    1. Other co-morbid neurologic diagnoses (eg. Parkinson's disease)

    2. Seizure disorder

    3. Enrolment in concurrent upper extremity intervention trial

    4. Metal implants in head

    5. significant upper extremity orthopedic issues

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Stroke Robotic and Recovery Lab, Foothills Medical Centre Calgary Alberta Canada T2N 2T9

    Sponsors and Collaborators

    • University of Calgary

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. Sean Dukelow, Associate Professor, MD PhD FRCPC, University of Calgary
    ClinicalTrials.gov Identifier:
    NCT03888326
    Other Study ID Numbers:
    • REB17-0938
    First Posted:
    Mar 25, 2019
    Last Update Posted:
    Mar 25, 2019
    Last Verified:
    Mar 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Dr. Sean Dukelow, Associate Professor, MD PhD FRCPC, University of Calgary
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 25, 2019